1. Key Insights

2. Report Introduction

3. Anorexia Nervosa Market Overview at a Glance
3.1. Market Share (%) Distribution of Anorexia Nervosa by Therapies in 2019
3.2. Market Share (%) Distribution of Anorexia Nervosa by Therapies in 2032

4. Anorexia Nervosa Market: Future Perspective

5. Executive Summary of Anorexia nervosa

6. Disease Background and Overview: Anorexia Nervosa (AN)
6.1. Introduction of Anorexia Nervosa
6.2. Types of Anorexia Nervosa
6.3. Risk factors of Anorexia Nervosa
6.4. Symptoms of Anorexia Nervosa
6.5. Comorbidities of Anorexia Nervosa
6.6. Etiology of Anorexia Nervosa
6.7. Pathophysiology of Anorexia Nervosa
6.8. Diagnostic Approach of Anorexia Nervosa
6.8.1. Diagnostic Guidelines
6.8.1.1. DSM-5 Diagnostic Criteria
6.8.1.2. ICD-11 diagnostic criteria (6B10)
6.8.1.3. ICD-10 diagnostic criteria (FB50.0)
6.8.1.4. German Guidelines on Fluency Disorders based on ICF mode
6.9. Treatment and Management of Anorexia Nervosa
6.9.1. Treatment Algorithm
6.9.2. Treatment Guidelines
6.9.2.1. AAFP Key Recommendations:
6.9.2.2. German Guidelines
6.9.2.3. WFSBP Guidelines for the Pharmacological Treatment of Eating Disorders
6.9.2.4. APA Practice Guidelines
6.9.2.5. NICE Guidelines

7. Epidemiology and Patient Population
7.1. Key Findings
7.2. Methodology of Epidemiology
7.3. Assumptions and Rationale: 7MM
7.4. Total Prevalent Cases of Anorexia Nervosa in the 7MM
7.5. Total Diagnosed Prevalent Cases of Anorexia Nervosa in the 7MM
7.6. The United States
7.6.1. Total Prevalent Cases of Anorexia Nervosa in the United States
7.6.2. Total Diagnosed Prevalent Cases of Anorexia Nervosa in the United States
7.6.3. Gender-specific Diagnosed Prevalent Cases of Anorexia Nervosa in the US
7.7. Major Five European Countries
7.7.1 Germany
7.7.1.1. Total Prevalent Cases of Anorexia Nervosa in Germany
7.7.2.2. Total Diagnosed Prevalent Cases of Anorexia Nervosa in Germany
7.7.3.3. Gender-specific Diagnosed Prevalent Cases of Anorexia Nervosa in Germany
7.7.2. France
7.7.2.1. Total Prevalent Cases of Anorexia Nervosa in France
7.7.2.2. Total Diagnosed Prevalent Cases of Anorexia Nervosa in France
7.7.2.3. Gender-specific Diagnosed Prevalent Cases of Anorexia Nervosa in France
7.7.3. Italy
7.7.3.1. Total Prevalent Cases of Anorexia Nervosa in Italy
7.7.3.2. Total Diagnosed Prevalent Cases of Anorexia Nervosa in Italy
7.7.3.3. Gender-specific Diagnosed Prevalent Cases of Anorexia Nervosa in Italy
7.7.4. Spain
7.7.4.1. Total Prevalent Cases of Anorexia Nervosa in Spain
7.7.4.2. Total Diagnosed Prevalent Cases of Anorexia Nervosa in Spain
7.7.4.3. Gender-specific Diagnosed Prevalent Cases of Anorexia Nervosa in Spain
7.7.5. UK
7.7.5.1. Total Prevalent Cases of Anorexia Nervosa in the UK
7.7.5.2. Total Diagnosed Prevalent Cases of Anorexia Nervosa in the UK
7.7.5.3. Gender-specific Diagnosed Prevalent Cases of Anorexia Nervosa in the UK
7.8. Japan
7.8.1. Total Prevalent Cases of Anorexia Nervosa in Japan
7.8.2. Total Diagnosed Prevalent Cases of Anorexia Nervosa in Japan
7.8.3. Gender-specific Diagnosed Prevalent Cases of Anorexia Nervosa in Japan

8. Patient Journey

9. Emerging Drugs
9.1. Key Cross Competition
9.2. Psilocybin: COMPASS Pathways
9.2.1. Product Description
9.2.2. Other Development Activities
9.2.3. Clinical Development
9.2.4. Clinical Trials Information
9.2.5. Safety and Efficacy
9.2.6. Product Profile
9.2.7. Analysts' Views
9.3. Ketamine: Homeostasis Therapeutics, LLC
9.3.1. Product Description
9.3.2. Other Development Activities
9.3.3. Clinical Development
9.3.4. Clinical Trials Information
9.3.5. Product Profile

10. Anorexia nervosa: Seven Major Market Analysis
10.1. Key Findings
10.2. Methodology of Anorexia nervosa Market
10.3. Market Outlook
10.4. Potential of Emerging Therapies
10.5. Key Market Forecast Assumptions
10.6. Market Size of Anorexia Nervosa in the 7MM
10.7. Market Size of Anorexia Nervosa by Therapies in the 7MM
10.8. Market Size of Anorexia Nervosa in the United States
10.8.1. Total Market Size of Anorexia Nervosa
10.8.2. Market Size of Anorexia Nervosa by Therapies
10.9. Market Size of Anorexia Nervosa in the EU-5
10.9.1. Market Size of Anorexia Nervosa in the Germany
10.9.1.1. Total Market Size of Anorexia Nervosa
10.9.1.2. Market Size of Anorexia Nervosa by Therapies
10.9.2. Market Size of Anorexia Nervosa in the France
10.9.2.1. Total Market Size of Anorexia Nervosa
10.9.2.2. Market Size of Anorexia Nervosa by Therapies
10.9.3. Market Size of Anorexia Nervosa in the Italy
10.9.3.1. Total Market Size of Anorexia Nervosa
10.9.3.2. Market Size of Anorexia Nervosa by Therapies
10.9.4. Market Size of Anorexia Nervosa in the Spain
10.9.4.1. Total Market Size of Anorexia Nervosa
10.9.4.2. Market Size of Anorexia Nervosa by Therapies
10.9.5. Market Size of Anorexia Nervosa in the UK
10.9.5.1. Total Market Size of Anorexia Nervosa
10.9.5.2. Market Size of Anorexia Nervosa by Therapies
10.10. Market Size of Anorexia Nervosa in Japan
10.10.1. Total Market Size of Anorexia Nervosa
10.10.2. Market Size of Anorexia Nervosa by Therapies

11. Key Opinion Leaders' Views

12. Market Drivers

13. Market Barriers

14. SWOT Analysis

15. Unmet Needs

16. Reimbursement and Market Access

17. Appendix
17.1. Bibliography
17.2. Report Methodology

18. DelveInsight Capabilities

19. Disclaimer

20. About DelveInsight

List of Tables
Table 1: Summary of AN Market and Epidemiology (2019-2032)
Table 2: Severity Specific Classification
Table 3: Total Prevalent Cases of Anorexia Nervosa In the 7MM, in ‘000' (2019-2032)
Table 4: Total Diagnosed Prevalent Cases of Anorexia Nervosa in the 7MM, in ‘000' (2019-2032)
Table 5: Total Prevalent Cases of Anorexia Nervosa in the US, in ‘000' (2019-2032)
Table 6: Total Diagnosed Prevalent Cases of Anorexia Nervosa in the US, in ‘000' (2019-2032)
Table 7: Gender-specific Diagnosed Prevalent Cases of Anorexia Nervosa in the US, in ‘000' (2019-2032)
Table 8: Total Prevalent Cases of Anorexia Nervosa in Germany, in ‘000' (2019-2032)
Table 9: Total Diagnosed Prevalent Cases of Anorexia Nervosa in Germany, in ‘000' (2019-2032)
Table 10: Gender-specific Diagnosed Prevalent Cases of Anorexia Nervosa in Germany, in ‘000' (2019-2032)
Table 11: Total Prevalent Cases of Anorexia Nervosa in France, in ‘000' (2019-2032)
Table 12: Total Diagnosed Prevalent Cases of Anorexia Nervosa in France, in ‘000' (2019-2032)
Table 13: Gender-specific Diagnosed Prevalent Cases of Anorexia Nervosa in France, in ‘000' (2019-2032)
Table 14: Total Prevalent Cases of Anorexia Nervosa in Italy, in ‘000' (2019-2032)
Table 15: Total Diagnosed Prevalent Cases of Anorexia Nervosa in Italy, in ‘000' (2019-2032)
Table 16: Gender-specific Diagnosed Prevalent Cases of Anorexia Nervosa in Italy, in ‘000' (2019-2032)
Table 17: Total Prevalent Cases of Anorexia Nervosa in Spain, in ‘000' (2019-2032)
Table 18: Total Diagnosed Prevalent Cases of Anorexia Nervosa in Spain, in ‘000' (2019-2032)
Table 19: Gender-specific Diagnosed Prevalent Cases of Anorexia Nervosa in Spain, in ‘000' (2019-2032)
Table 20: Total Prevalent Cases of Anorexia Nervosa in the UK, in ‘000' (2019-2032)
Table 21: Total Diagnosed Prevalent Cases of Anorexia Nervosa in the UK, in ‘000' (2019-2032)
Table 22: Gender-specific Diagnosed Prevalent Cases of Anorexia Nervosa in the UK, in ‘000' (2019-2032)
Table 23: Total Prevalent Cases of Anorexia Nervosa in Japan, in ‘000' (2019-2032)
Table 24: Total Diagnosed Prevalent Cases of Anorexia Nervosa in Japan, in ‘000' (2019-2032)
Table 25: Gender-specific Diagnosed Prevalent Cases of Anorexia Nervosa in Japan, in ‘000' (2019-2032)
Table 26: Comparison of emerging drugs under development
Table 27: Psilocybin, Clinical Trial Description, 2022
Table 28: Ketamine, Clinical Trial Description, 2022
Table 29: Key Market Forecast Assumptions for Psilocybin
Table 30: Market Size of Anorexia Nervosa in the 7MM in USD Million (2019-2032)
Table 31: Market Size of Anorexia Nervosa by Therapies in the 7MM in USD Million (2019-2032)
Table 32: United States Market Size of Anorexia Nervosa in USD Million (2019-2032)
Table 33: Market Size of Anorexia Nervosa by Therapies in the US in USD Million (2019-2032)
Table 34: EU-5 Market Size of Anorexia Nervosa, in USD Million (2019-2032)
Table 35: Market Size of Anorexia Nervosa by Therapies in the EU5, in USD Million (2019-2032)
Table 36: Market size of Anorexia Nervosa in Germany, in USD Million (2019-2032)
Table 37: Market Size of Anorexia Nervosa by Therapies in Germany, in USD Million (2019-2032)
Table 38: Market size of Anorexia Nervosa in France, in USD Million (2019-2032)
Table 39: Market Size of Anorexia Nervosa by Therapies in France, in USD Million (2019-2032)
Table 40: Market size of Anorexia Nervosa in Italy, in USD Million (2019-2032)
Table 41: Market Size of Anorexia Nervosa by Therapies in Italy, in USD Million (2019-2032)
Table 42: Market size of Anorexia Nervosa in Spain, in USD Million (2019-2032)
Table 43: Market Size of Anorexia Nervosa by Therapies in Spain, in USD Million (2019-2032)
Table 44: Market size of Anorexia Nervosa in UK, in USD Million (2019-2032)
Table 45: Market Size of Anorexia Nervosa by Therapies in the UK, in USD Million (2019-2032)
Table 46: Market Size of Anorexia Nervosa in Japan, in USD Million (2019-2032)
Table 47: Market Size of Anorexia Nervosa by Therapies in Japan, in USD Million (2019-2032)

List of Figures
Figure 1: Types of Eating Disorder
Figure 2: Types of Anorexia Nervosa
Figure 3: Physical Signs and Effects of Anorexia Nervosa
Figure 4: Medical Complications
Figure 5: Psychiatric Comorbidity
Figure 6: Stepwise approach to managing Anorexia Nervosa
Figure 7: Key Strategies for Treatment of AN
Figure 8: Phases of FBT
Figure 9: Phases of FPT
Figure 10: Anorexia Nervosa Treatment Algorithm
Figure 11: Total Prevalent Cases of Anorexia Nervosa In the 7MM, in ‘000' (2019-2032)
Figure 12: Total Diagnosed Prevalent Cases of Anorexia Nervosa in the 7MM, in ‘000' (2019-2032)
Figure 13: Total Prevalent Cases of Anorexia Nervosa in the United States, in ‘000' (2019-2032)
Figure 14: Total Diagnosed Prevalent Cases of Anorexia Nervosa in the US, in ‘000' (2019-2032)
Figure 15: Gender-specific Diagnosed Prevalent Cases of Anorexia Nervosa in the US, in ‘000' (2019-2032)
Figure 16: Total Prevalent Cases of Anorexia Nervosa in Germany, in ‘000' (2019-2032)
Figure 17: Total Diagnosed Prevalent Cases of Anorexia Nervosa in Germany, in ‘000' (2019-2032)
Figure 18: Gender-specific Diagnosed Prevalent Cases of Anorexia Nervosa in Germany, in ‘000' (2019-2032)
Figure 19: Total Prevalent Cases of Anorexia Nervosa in France, in ‘000' (2019-2032)
Figure 20: Total Diagnosed Prevalent Cases of Anorexia Nervosa in France, in ‘000' (2019-2032)
Figure 21: Gender-specific Diagnosed Prevalent Cases of Anorexia Nervosa in France, in ‘000' (2019-2032)
Figure 22: Total Prevalent Cases of Anorexia Nervosa in Italy, in ‘000' (2019-2032)
Figure 23: Total Diagnosed Prevalent Cases of Anorexia Nervosa in Italy, in ‘000' (2019-2032)
Figure 24: Gender-specific Diagnosed Prevalent Cases of Anorexia Nervosa in Italy, in ‘000' (2019-2032)
Figure 25: Total Prevalent Cases of Anorexia Nervosa in Spain, in ‘000' (2019-2032)
Figure 26: Total Diagnosed Prevalent Cases of Anorexia Nervosa in Spain, in ‘000' (2019-2032)
Figure 27: Gender-specific Diagnosed Prevalent Cases of Anorexia Nervosa in Spain, in ‘000' (2019-2032)
Figure 28: Total Prevalent Cases of Anorexia Nervosa in the UK, in ‘000' (2019-2032)
Figure 29: Total Diagnosed Prevalent Cases of Anorexia Nervosa in the UK, in ‘000' (2019-2032)
Figure 30: Gender-specific Diagnosed Prevalent Cases of Anorexia Nervosa in the UK, in ‘000' (2019-2032)
Figure 31: Total Prevalent Cases of Anorexia Nervosa in Japan, in ‘000' (2019-2032)
Figure 32: Total Diagnosed Prevalent Cases of Anorexia Nervosa in Japan, in ‘000' (2019-2032)
Figure 33: Gender-specific Diagnosed Prevalent Cases of Anorexia Nervosa in Japan, in ‘000' (2019-2032)
Figure 34: Patient Journey
Figure 35: Market Size of Anorexia Nervosa in the 7MM, in USD Million (2019-2032)
Figure 36: Market Size of Anorexia Nervosa by Therapies in the 7MM in USD Million (2019-2032)
Figure 37: Market Size of Anorexia Nervosa in the United States, USD Million (2019-2032)
Figure 38: Market Size of Anorexia Nervosa by Therapies in the United States, in USD Million (2019-2032)
Figure 39: Market Size of Anorexia Nervosa in the EU-5, USD Million (2019-2032)
Figure 40: Market Size of Anorexia Nervosa by Therapies, in the EU-5, in USD Million (2019-2032)
Figure 41: Market size of Anorexia Nervosa in Germany, in USD Million (2019-2032)
Figure 42: Market Size of Anorexia Nervosa by Therapies in Germany, in USD Million (2019-2032)
Figure 43: Market size of Anorexia Nervosa in France, in USD Million (2019-2032)
Figure 44: Market Size of Anorexia Nervosa by Therapies in France, in USD Million (2019-2032)
Figure 45: Market size of Anorexia Nervosa in Italy, in USD Million (2019-2032)
Figure 46: Market Size of Anorexia Nervosa by Therapies in Italy, in USD Million (2019-2032)
Figure 47: Market size of Anorexia Nervosa in Spain, in USD Million (2019-2032)
Figure 48: Market Size of Anorexia Nervosa by Therapies in Spain, in USD Million (2019-2032)
Figure 49: Market size of Anorexia Nervosa in UK, in USD Million (2019-2032)
Figure 50: Market Size of Anorexia Nervosa by Therapies in the UK, in USD Million (2019-2032)
Figure 51: Market Size of Anorexia Nervosa in Japan, USD Million (2019-2032)
Figure 52: Market Size of Anorexia Nervosa by Therapies in Japan, in USD Million (2019-2032)
Figure 53: Market Drivers
Figure 54: Market Barriers
Figure 55: SWOT Analysis
Figure 56: Unmet Needs

Key Companies
COMPASS Pathways
Homeostasis Therapeutics, LLC